Men’s health issues range from fertility concerns (including erectile dysfunctions, penis, testicles and prostate issues), to emotional and physical issues, all of which are of medical concern. The appraised contemporary News item concerning men is the novel method of testing and identifying men who are in need of chemotherapy.
According to pharmaceutical giant Pfizer, a novel method of testing and identifying men who are at risk of relapsing from cancer of the testicles has been discovered. This process is achievable by merely evaluating non-seminomatous tumor germ cells (these are common presentations of cancer of the testicles). Through this discovery, scientists can now identify men who have a higher propensity to relapse even in the event that no tumor spread can be identified.
Information published by Pfizer indicate that Caucasian men take the lead among the men who present with testicular germ cell tumors - the commonest form of malignant tumor. The profoundness of this medical issue is such that the affected men are often in a quandary whether to monitor or treat the condition in the event of a relapse, or whether to immediately opt for chemotherapy, even though chemotherapy is known for its long term negative effects.
The ability to predict the likely recipients of chemotherapy is vital in minimizing chemo treatment and its subsequent undesirable side effects. This novel test that has been discovered comes in handy and it is useful for clinics in determining the recipients of chemotherapy.
In a study by the UK based Cancer Research Institute, tumor samples were analyzed among patients presenting with stage 1 non seminomatous tumors who took part in the clinical trial. Three key characteristics of the tumors where discovered to influence the propensity to relapse among men patients. These factors included the presence of blood vessels in the tumor, the presence of cancer stem cells in the tumors and finally the percentage of molecule CXCL 12 in the tumors.
This new discovery thus helps in the testing and identifying the most ideal patients for chemotherapy. In as much as chemotherapy is effective in dealing with cancer of the testicles, its long term effects on the patients are equally dire. The negative effects range from health issues such as the risk of malignancies, to the risk of cardio vascular diseases and other conditions such as Raynaud’s syndrome and neuropathy. A patient who has undergone chemotherapy is also at risk of developing emotional disorders. Additionally, minimizing exposure to chemotherapy is beneficial to younger men since its effects can stay with them for decades.
With this breakthrough advancement therefore, monitoring low risk patients is possible and chemotherapy can be avoided alongside its effects.